Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.

@article{Hummel2009ExploratoryAO,
  title={Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.},
  author={J{\"u}rgen Hummel and Sue McKendrick and Charles J. Brindley and Raymond David French},
  journal={Pharmaceutical statistics},
  year={2009},
  volume={8 1},
  pages={
          38-49
        }
}
This article reviews currently used approaches for establishing dose proportionality in Phase I dose escalation studies. A review of relevant literature between 2002 and 2006 found that the power model was the preferred choice for assessing dose proportionality in about one-third of the articles. This article promotes the use of the power model and a conceptually appealing extension, i.e. a criterion based on comparing the 90% confidence interval for the ratio of predicted mean values from the… 
View on PubMed
kinetassist.com
92 Citations
Highly Influential Citations
8
Background Citations
13
Methods Citations
18
Results Citations
1

Figures and Tables from this paper

92 Citations

Citation Type

Citation Type

Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
TLDR
A Bayesian approach to incorporating PK assessment into OD estimation in a dose-finding trial is proposed and shows that compared with standard methods, the proposed method may be better able to select the correct ODs across a variety of realistic settings.
Assessing goodness-of-fit for evaluation of dose-proportionality.
TLDR
This work proposes the use of simulation-based visual predictive checks to improve the validity of dose-proportionality conclusions for complex designs and provides an illustrative example.
To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics
TLDR
A decision tree is presented that evaluates concerns about non-linearities raised in the preclinical phase and their potential impact on the proportionality between microdose and intended therapeutic dose as predicted from preclinical information.
An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
  • P. Paixão, L. Gouveia, J. Morais
  • Medicine
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2012
Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development
This article provides an overview of four case studies to demonstrate the utility of pharmacometric analysis in biosimilar development to help design sensitive clinical pharmacology studies for the…
Pharmacokinetics of single‐dose sildenafil administered orally in clinically healthy dogs: Effect of feeding and dose proportionality
TLDR
The pharmacokinetic properties of oral sildenafil and the effect of feeding and dose proportionality were described and well tolerated in all studies and nonproportional increases in AUCinf and Cmax at 1-4 mg/kg doses were detected by a power model analysis.
Dose Proportionality of Once‐Daily Trazodone Extended‐Release Caplets Under Fasting Conditions
TLDR
Dose proportionality of intact and bisected caplets of TzCOAD was evaluated in a single‐dose, randomized, 5‐way crossover study and the conclusion of dose proportionality was generally supported using the bioequivalence approach.
Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6
TLDR
Simulation results confirmed that a loading dose regimen either of administration at weeks 0, 2, and 6 or doubling the maintenance dose level, followed by maintenance dosing of 75–150 mg every 8 weeks, was expected to provide a best risk/benefit ratio in future clinical studies.
Assessment of Dose Proportionality of Rivaroxaban Nanocrystals
TLDR
The preparation of a nanocrystal formulation of RXB improved its dissolution rate and pharmacokinetic profile and the dose proportionality for AUC was achieved at doses between 10–15 and 3–15 mg/kg.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
TLDR
The safety, pharmacokinetic, and pharmacodynamic profiles of atacicept in healthy Japanese subjects were comparable to those in healthy Caucasian subjects and there were no statistically significant differences between ethnicities in the pharmacokinetics–dose relationship.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Confidence Interval Criteria for Assessment of Dose Proportionality
TLDR
A pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common study designs and helps to standardize decision rules is proposed.
Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party
TLDR
The methods of statistical analysis of dose proportionality studies have been reviewed and if there is doubt over the goodness of fit of the power model then analysis of variance (after log transformation) together with pairwise comparisons between doses provides a suitable alternative approach.
Continual reassessment method: a practical design for phase 1 clinical trials in cancer.
TLDR
A new approach to the design and analysis of Phase 1 clinical trials in cancer and a particularly simple model is looked at that enables the use of models whose only requirements are that locally they reasonably well approximate the true probability of toxic response.
Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers.
TLDR
A Bayesian decision procedure is developed for choosing the doses to give in the next round of the study, taking into account both prior information and the responses observed so far, subject to a constraint which reduces the risk of administering dangerously high doses.
Sample size calculation for the Power Model for dose proportionality studies.
TLDR
Analytical derivations of sample sizes for various designs (including crossover, incomplete block and parallel group designs) are proposed to be analysed according to the mixed effects Power Model.
Optimizing First-Time-in-Human Trial Design for Studying Dose Proportionality
TLDR
The conclusion is that an alternate panel design always requires fewer subjects than a sequential panel design, and in many common cases, less than half as many subjects are required.
Gaining acceptability for the Bayesian decision-theoretic approach in dose-escalation studies
TLDR
The authors look into the Bayesian decision-theoretic approach and use simulation as a tool to investigate the impact of compromises with conventional practice that might make the procedures more acceptable for implementation.
How First‐Time‐in‐Human Studies Are Being Performed: A Survey of Phase I Dose‐Escalation Trials in Healthy Volunteers Published Between 1995 and 2004
TLDR
One hundred five studies comprising 3323 healthy volunteers published in the 5 major clinical pharmacology journals since 1995 were analyzed, finding the parallel single‐dose design was the most common design and crossover designs were more frequent in the early publications.
Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule.
TLDR
Data collected from this study demonstrate the dose proportionality of the new 10 mg and 30 mg dosage strengths of MPH ER capsules with the 20 mg capsule, and the availability and predictability of these dosage strengths should facilitate dose titration of ADHD patients.
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
TLDR
The incidences of dose-limiting toxicity, principally neutropenia and thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m(2), which was determined to be the maximum tolerated dose (MTD) for both minimally pretreated and heavily pretreated patients.
...
1
2
3
4
5
...